title: The Italian AIPO study on tuberculosis treatment results, report 1996. National AIPO "Tuberculosis" Study Group. Associazione Italiana Pneumologi Ospedalieri.
abstract: In Italy, no national data on tuberculosis (TB) treatment results were available. In 1995, the AIPO (Italian Association of Hospital Pneumologists) TB Study Group, in collaboration with the Istituto Superiore di Sanità (technical branch of the Ministry of Health), started a prospective monitoring activity based on World Health Organization (WHO) and International Union against Tuberculosis and Lung Disease (IUATLD) recommendations. Data were collected from a nationwide network of 41 TB units, managing a significant proportion of all the TB cases notified in Italy each year. The aim of this study was to analyse the case findings and treatment results for the year 1996. Eight hundred and thirty eight TB cases were reported (56% males; 26% immigrants), 708 (84%) being new cases. Of these cases, 565 (67%) were pulmonary, 235 (28%) extrapulmonary and 38 (5%) both pulmonary and extrapulmonary. The main risk factors for TB were a history of recent contact and diabetes among native Italians and recent contact and human immunodeficiency virus-seropositive status among immigrants. The majority of immigrants were from Africa and Asia, and had been in Italy > 24 months before diagnosis of TB. Thirty-six per cent of patients had a positive direct sputum smear examination for alcohol acid-fast bacilli; 37% were resistant to any drug (monoresistance to isoniazid 4.4%; multidrug resistance 10.4%). In 96% of cases, the duration of treatment was < 12 months. The overall success rate (cured plus treatment completed) was 84.1%. A significantly higher percentage of deaths was found in native Italians (being age-related), whereas immigrants had a higher default rate.
authors.affiliation: Istituto Villa Marelli per la Patologia del Torace, Milan, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Ambrosetti
authors.forename: G
authors.initials: G
authors.lastname: Besozzi
authors.forename: B
authors.initials: B
authors.lastname: Farris
authors.forename: S
authors.initials: S
authors.lastname: Nutini
authors.forename: L
authors.initials: L
authors.lastname: Saini
authors.forename: L
authors.initials: L
authors.lastname: Casali
authors.forename: P
authors.initials: P
authors.lastname: Pretto
authors.forename: G
authors.initials: G
authors.lastname: Orani
authors.forename: S
authors.initials: S
authors.lastname: Calabro
authors.forename: G B
authors.initials: GB
authors.lastname: Migliori
mesh_terms: D000995:Antitubercular Agents / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D004641:Emigration and Immigration; D005260:Female; D006801:Humans; D015994:Incidence; D007558:Italy / Q000453:epidemiology; D008297:Male; D017063:Outcome Assessment, Health Care; D011446:Prospective Studies; D012307:Risk Factors; D016896:Treatment Outcome; D014376:Tuberculosis / Q000188:drug therapy* / Q000453:epidemiology
chemical_list: D000995:Antitubercular Agents